Almost A Million People Inoculated With Chinese Covid 19 Vaccine: Firm

Marco Green
November 22, 2020

Almost one million people have taken an experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) through the country's emergency use programme, the firm said late on Wednesday.

As of November 19, almost a million people in China have taken an experimental coronavirus vaccine through the country's emergency use program.

China initiated the emergency use program in July.

Besides the recipients of the Sinopharm jabs, authorities in Zhejiang said they had made a COVID-19 vaccine developed by the privately owned pharmaceutical company Sinovac Biotec available to high-risk groups in the east China province under the emergency use scheme.

China has been giving experimental Covid-19 vaccines to people including state employees, worldwide students, and essential workers heading overseas since July.

Competition has intensified among pharmaceutical companies racing to develop a Covid-19 shot, with two vaccines - one by USA company Pfizer and its German partner BioNTech, and another by U.S. firm Moderna - publishing large-scale trial data this month that showed their jabs were around 95 percent effective against Covid-19.

"In terms of emergency use, the vaccines were applied to almost a million people and there has not been a single case of a serious adverse event. People have had only mild symptoms", Liu Jingzhen, chairman of China National Pharmaceutical Group (Sinopharm), said.

"Inducing robust immune responses in older adults has been a long-standing challenge in human vaccine research", Dr Angela Minassian, Investigator at the University of Oxford and Honorary Consultant in Infectious Diseases said in a statement.

The comments from Professor Andrew Pollard, study lead from the University of Oxford, per the BBC, come amid news on Thursday that the vaccine induced an immune response, including in participants over age 70, per phase 2 trial data.

The Sinopharm Company vaccine is now undergoing human testing of the third barn.

Since the announcement by the American company Pfizer to make 95 percent effective corona vaccine, many countries have claimed to make effective vaccine.

On Monday, U.S. company Moderna said its version, mRNA-1273, had an efficacy of 94.5 percent in phase 3 clinical trials.

Compared with other Covid-19 vaccine candidates such as viral-vectored vaccines or DNA or RNA vaccines, according to the researchers, the occurrence of fever after vaccination with CoronaVac was relatively low. Demand is clearly high, and several wealthy nations already have their pre-orders in place.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER